The Latest Breaking News from GSK

Pfizer is also facing off with collaborators Sanofi and AstraZeneca Plc to develop prevention for dangerous RSV infections in newborns, a market that could reach $1.5 billion.

WASHINGTON — Pfizer Inc.’s vaccine for respiratory syncytial virus received endorsement from a key panel of U.S. advisers for its safety in people 60 and older, a key endorsement for the drugmaker’s potential product.

Here is the full list of respondents and their feedback to a Evening Standard survey looking at weekly working patterns, writes Joanna Hodgson

A glitch in a law may make it difficult for children from low-income families to get the new RSV vaccine

Unite chiefs say their members are determined to get 'what they are owed' in bonus payments row.

The pharmaceutical industry is well-positioned for significant growth in the near future, given the growing demand for medicines and increasing R&D activities. Given the industry's inelastic demand, fundamentally strong pharma stocks AstraZeneca (AZN), Bristol-Myers Squibb (BMY), and GSK plc (GSK) might be solid long-term investments. Continue reading….

Emma Walmsley says ambition to be pharma superpower at risk unless improvements made in key areas

Interest rates are today expected to rise another 0.5% to 4% as the Bank of England continues the fight against inflation with its 10th increase in a row.

Experts are calling gepotidacin a massive step forwards in the fight against resistance to antibiotics